Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2014年 / 12卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [31] Intralesional brentuximab vedotin for the treatment of primary cutaneous T-cell lymphomas: a case series
    Arroyo-Andres, Jorge
    Agud-Dios, Manuel
    Rubio-Muniz, Carmen A.
    Postigo, Concepcion
    Cortijo-Cascajares, Susana
    Ortiz-Romero, Pablo L.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2024, 63 (02) : e57 - e59
  • [32] Primary cutaneous T-cell lymphomas other than mycosis fungoides and primary cutaneous CD30(+) lymphoproliferative disorders
    Ozbalak, Murat
    Demirkesen, Cuyan
    Oguz, Oya
    Onsun, Nahide
    Tuzuner, Nukhet
    VIRCHOWS ARCHIV, 2007, 451 (02) : 456 - 456
  • [33] Primary cutaneous CD30+ lymphoproliferative disorders have a CD4+ cytotoxic T cell phenotype
    Vermeer, MH
    Kummer, JA
    Meijer, CJLM
    Willemze, MR
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 109 (03) : 490 - 490
  • [34] Transformed Mycosis Fungoides and Mimics: Exploring the Landscape of CD30+ Cutaneous T-Cell Lymphomas
    Merechi, Fikru
    Koka, Rima
    Singh, Zeba
    Lee, Seung Tae
    Kallen, Michael E.
    AJSP-REVIEWS AND REPORTS, 2019, 24 (05): : 196 - 200
  • [35] Primary Cutaneous CD30+ Lymphoproliferative Disorders: a Comprehensive Review
    Cosimo Di Raimondo
    Vishwas Parekh
    Joo Y. Song
    Steven T. Rosen
    Christiane Querfeld
    Jasmine Zain
    Xochiquetzal U. Martinez
    Farah R. Abdulla
    Current Hematologic Malignancy Reports, 2020, 15 : 333 - 342
  • [36] Pleiotropic effects of CD30-CD30L interaction on primary cutaneous CD30+ T-cell lymphomas.
    Mori, M
    Manuelli, C
    Pimpinelli, N
    Santucci, M
    Cappugi, P
    Giannotti, B
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 109 (03) : 488 - 488
  • [37] Trial in Progress: A Phase 4 Multicenter Study of Brentuximab Vedotin Treatment in Chinese Patients with CD30Positive Cutaneous T-Cell Lymphoma
    Wang, Qian
    Jiang, Ming
    Zhang, Chunlei
    Wu, Sheng
    Jiang, Wenhan
    Ji, Meng
    Chen, Tong
    BLOOD, 2022, 140 : 12044 - 12045
  • [38] Brentuximab vedotin in children and adolescents with CD30-positive lymphoproliferative disorders
    Kozlov, Andrey
    Gevorgian, Asmik
    Kazantsev, Ilya
    Tolkunova, Polina
    Vigovskaya, Elena
    Eltsov, Anton
    Nikolaev, Ilya
    Morozova, Elena
    Mihailova, Natalya
    Zubarovskaya, Ludmila
    Afanasyev, Boris
    BONE MARROW TRANSPLANTATION, 2018, 53 : 602 - 603
  • [39] Signet Ring Cell Primary Cutaneous CD30+ Lymphoproliferative Disorder Presenting as a Monomorphic T-Cell Posttransplant Lymphoproliferative Disease
    Papalas, John A.
    Kulbacki, Evan L.
    Park, H. Kim
    Howell, Eric R.
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2012, 34 (07) : E94 - E96
  • [40] Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+mature T-cell lymphomas (MTCL).
    O'Connor, Owen A.
    Pro, Barbara
    Illidge, Tim
    Trumper, Lorenz H.
    Larsen, Emily K.
    Manley, Thomas John
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345